ZOELY nomegestrol acetate 2.5 mg and estradiol 1.5 mg tablet blister pack Australie - anglais - Department of Health (Therapeutic Goods Administration)

zoely nomegestrol acetate 2.5 mg and estradiol 1.5 mg tablet blister pack

theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.

MEGACE ES- megesterol acetate suspension États-Unis - anglais - NLM (National Library of Medicine)

megace es- megesterol acetate suspension

physicians total care, inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace® es oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). enter section text here therapy with megestrol acetate for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megestrol acetate is not intended for prophylactic use to avoid weight loss. enter section text here history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy. enter section text here pregnancy category x [ see warnings and precautions: (5.2)]. no adequate animal teratology information is available at clinically relevant doses. pregnant rats treated with low doses of megestrol acetate (0.02-fold the recommen

MEGACE ES- megesterol acetate suspension États-Unis - anglais - NLM (National Library of Medicine)

megace es- megesterol acetate suspension

endo pharmaceuticals inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - megace es is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). limitations of use therapy with megace es for weight loss should only be insti­tuted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megace es is not intended for prophylactic use to avoid weight loss. - history of hypersensitivity to megestrol acetate or any component of the formulation. - pregnancy [see warnings and precautions (5.2), use in specific populations (8.1, 8.3)]. risk summary based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see contraindications (4)] . there are no available human data to assess for any drug-associated risks of miscar

MEGACE ES- megesterol acetate suspension États-Unis - anglais - NLM (National Library of Medicine)

megace es- megesterol acetate suspension

par pharmaceutical, inc - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - other treatable causes prophylactic use megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. megestrol acetate has had limited use in hiv infected women. all 10 women in the clinical trials reported breakthrough bleeding. megace® es is a progesterone derivative, which may induce vaginal bleeding in women.

MEGACE ES- megesterol acetate suspension États-Unis - anglais - NLM (National Library of Medicine)

megace es- megesterol acetate suspension

atlantic biologicals corps - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 125 mg in 1 ml - other treatable causes prophylactic use megestrol acetate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. megestrol acetate has had limited use in hiv infected women. all 10 women in the clinical trials reported breakthrough bleeding. megace es is a progesterone derivative, which may induce vaginal bleeding in women. ®

Megace 40 mg/ml oral suspension Irlande - anglais - HPRA (Health Products Regulatory Authority)

megace 40 mg/ml oral suspension

originalis b.v. - megestrol acetate - oral suspension - 40 milligram(s)/millilitre - megestrol

APO-MEGESTROL TABLET 160 mg Singapour - anglais - HSA (Health Sciences Authority)

apo-megestrol tablet 160 mg

pharmaforte singapore pte ltd - megestrol acetate - tablet - 160 mg - megestrol acetate 160 mg

APO-MEGESTROL TABLET 40 mg Singapour - anglais - HSA (Health Sciences Authority)

apo-megestrol tablet 40 mg

pharmaforte singapore pte ltd - megestrol acetate - tablet - 40 mg - megestrol acetate 40 mg

MEGESTROL ACETATE Australie - anglais - APVMA (Australian Pesticides and Veterinary Medicines Authority)

megestrol acetate

intervet australia pty limited - megestrol acetate - unknown - megestrol acetate steroid-progestin active 0.0 - active constituent